Xencor Presents Preclinical Data From Multiple XmAb Research Programs At The SITC Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Xencor has presented preclinical data from multiple XmAb research programs at the SITC Annual Meeting. The company is conducting a Phase 1 study of XmAb808 in patients with advanced solid tumors. Xencor also engineered stabilized, potency-modulated IL-18 cytokines fused to an XmAb heterodimeric Fc domain with Xtend™ Fc technology for longer half-life (IL18-Fc). Further, Xencor's XmAb natural killer cell engagers (NKEs) are multifunctional antibodies that target multiple activating receptors on the surface of NK cells and bind to tumor-associated antigens.
November 03, 2023 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xencor's presentation of preclinical data from multiple XmAb research programs could potentially boost investor confidence in the company's research and development capabilities.
The presentation of preclinical data from multiple XmAb research programs demonstrates Xencor's ongoing commitment to research and development. This could potentially boost investor confidence in the company's ability to develop innovative treatments, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100